Gouji Toyokawa
Overview
Explore the profile of Gouji Toyokawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
172
Citations
3156
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hashinokuchi A, Akamine T, Toyokawa G, Matsudo K, Nagano T, Kinoshita F, et al.
Interdiscip Cardiovasc Thorac Surg
. 2024 Dec;
40(1).
PMID: 39705189
Objectives: Spread through air spaces (STAS) is considered a poor prognostic factor in patients with resected non-small lung cell cancer; however, the clinical significance of STAS extent remains unclear. We...
2.
Matsudo K, Takamori S, Takenaka T, Shimokawa M, Hashinokuchi A, Nagano T, et al.
Transpl Int
. 2024 Nov;
37:13227.
PMID: 39524044
Bronchiolitis obliterans syndrome (BOS) is a chronic complication following lung transplantation that limits the long-term survival. Although the enhancer of zeste homolog 2 (EZH2) is involved in post-transplantation rejection, its...
3.
Nagata Y, Toyokawa G, Sugiyama A, Shimamatsu S, Saitoh O, Okubo H, et al.
J Oncol Pharm Pract
. 2024 Feb;
30(4):772-776.
PMID: 38404012
Introduction: Platinum-based chemotherapy is the mainstay of first-line therapy for advanced-stage non-small cell lung cancer (NSCLC). Although carboplatin-induced hypersensitivity reactions (HSRs) commonly occur following multiple cycles of therapy, they are...
4.
Kodama M, Toyokawa G, Sugahara O, Sugiyama S, Haratake N, Yamada Y, et al.
Cell Rep
. 2023 Aug;
42(8):112899.
PMID: 37531252
Small cell lung cancer (SCLC) is one of the deadliest human cancers, with a 5-year survival rate of ∼7%. Here, we performed a targeted proteomics analysis of human SCLC samples...
5.
Oku Y, Toyokawa G, Wakasu S, Kinoshita F, Takamori S, Watanabe K, et al.
Cancer Med
. 2023 May;
12(13):14327-14336.
PMID: 37211905
Background: Immunotherapy has become a standard-of-care for patients with non-small-cell lung cancer (NSCLC). Although several biomarkers, such as programmed cell death-1, have been shown to be useful in selecting patients...
6.
Toyokawa G, Bersani F, Bironzo P, Picca F, Tabbo F, Haratake N, et al.
Crit Rev Oncol Hematol
. 2023 Mar;
184:103966.
PMID: 36925092
The identification of actionable targets in oncogene-addicted non-small cell lung cancer (NSCLC) has fueled biomarker-directed strategies, especially in advanced stage disease. Despite the undeniable success of molecular targeted therapies, duration...
7.
Shimokawa M, Haratake N, Takada K, Toyokawa G, Takamori S, Mizuki F, et al.
Cancer Manag Res
. 2022 Sep;
14:2673-2680.
PMID: 36110158
Purpose: The incidence of delayed chemotherapy-induced nausea and vomiting (CINV) in patients with non-small cell lung cancer (NSCLC) receiving carboplatin (CBDCA)-based chemotherapy (CBDCA + pemetrexed or paclitaxel) has not been...
8.
Shoji F, Kozuma Y, Toyokawa G, Yamazaki K, Takeo S
JMA J
. 2021 Nov;
4(4):387-396.
PMID: 34796293
Introduction: Several immunonutritional supplements have recently been developed. However, improvements in preoperative immunonutritional conditions using these supplements have not been analyzed in patients undergoing thoracic surgery. Methods: This prospective, single-arm,...
9.
Yamazaki K, Toyokawa G, Kozuma Y, Shoji F, Shimokawa M, Takeo S
J Thorac Dis
. 2021 Oct;
13(9):5487-5495.
PMID: 34659815
Background: Robot-assisted thoracic surgery (RATS) lobectomy for lung cancer is now performed all around the world. The camera and robotic devices are generally inserted from a low position via the...
10.
Toyozawa R, Haratake N, Toyokawa G, Matsubara T, Takamori S, Miura N, et al.
JTO Clin Res Rep
. 2021 Sep;
1(2):100005.
PMID: 34589920
No abstract available.